Free Trial
NASDAQ:RVPH

Reviva Pharmaceuticals Q1 2023 Earnings Report

Reviva Pharmaceuticals logo
$0.82 +0.00 (+0.27%)
Closing price 05/9/2025 04:00 PM Eastern
Extended Trading
$0.82 +0.00 (+0.04%)
As of 05:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Reviva Pharmaceuticals EPS Results

Actual EPS
-$0.30
Consensus EPS
-$0.36
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Reviva Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Reviva Pharmaceuticals Announcement Details

Quarter
Q1 2023
Time
N/A
Conference Call Date
Monday, May 15, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Reviva Pharmaceuticals' Q1 2025 earnings is scheduled for Tuesday, May 13, 2025

Reviva Pharmaceuticals Earnings Headlines

Reviva Pharmaceuticals (RVPH) Projected to Post Earnings on Tuesday
Elon Set to Shock the World on June 1st?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.
RVPH: M&A Deals Highlight Brilaroxazine Value
See More Reviva Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Reviva Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Reviva Pharmaceuticals and other key companies, straight to your email.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals (NASDAQ:RVPH), a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

View Reviva Pharmaceuticals Profile

More Earnings Resources from MarketBeat